Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
C435S070100, C435S069100, C435S325000, C530S388230, C530S388150, C530S388100, C530S386000
The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5618700 (1997-04-01), Novick
patent: 5856135 (1999-01-01), Tsuchiya
patent: 7291721 (2007-11-01), Giles-Komar et al.
patent: 7560112 (2009-07-01), Chen et al.
patent: 7582298 (2009-09-01), Stevens et al.
patent: 2003/0229208 (2003-12-01), Queen et al.
patent: 2004/0081651 (2004-04-01), Karpusas et al.
patent: 2006/0257407 (2006-11-01), Chen et al.
patent: 2009/0297513 (2009-12-01), Garcia-Martinez et al.
patent: 2009/0317402 (2009-12-01), Rajpal et al.
Anderson et al. (2000) Hematology 147-165 “Multiple Myeloma: New Insights and Therapeutic Approaches”.
Benoy et al. (2002) Clin Breast Cancer 2(4):311-5 “Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients”.
Blay et al. (1992) Cancer Research 52:3317-3322 “Serum Level of Interleukin 6 as a Prognosis Factor in Metastatic Renal Cell Carcinoma”.
Bock et al. (1993) Cytokine 5(5):480-489 “Characterization of a new IL-6 dependent human B-lymphoma cell line in a long term culture”.
Brakenhoff et al. (1990) J. Immunol. 145:561-568 “Structure-function analysis of human IL-6. Epitope Mapping of Neutralizing Monoclonal Antibodies with Amino-and Carboxyl-Terminal Deletion Mutants”.
Cahlin et al. (2000) Cancer Research 60:5488-5493 “Experimental Cancer Cachexia: The Role of Host-derived Cytokines Interleukin (IL)-6, IL-12, Interferon-γ, and Tumor Necrosis Factor α Evaluated in Gene Knockout, Tumor-bearing Mice on C57 B1 Background and Eicosanoid-dependent Cachexia”.
Campbell et al. (1991) J. Clin. Invest. 87:739-742 “Essential Role for Interferon-gamma. And Interleukin-6 in Autoimmune Insulin-Dependent Diabetes in NOD/Wehi Mice”.
Capuron et al. (2001) Psychoneuroendocrinology 26(8):797-808 “Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy”.
Conze et al. (2001) Cancer Res 61:8851-8858 “Autocrine Production of Interleukin 6 Causes Multidrug Resistance in Breast Cancer Cells”.
Fumagalli et al. (1999) British J. Cancer 80(3-4):407-11 “Pretreatment serum markers and lymphocyte response to interleukin-2 therapy”.
Goswami et al. (1998) J. Neurochem 71:1837-1845 “Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG”.
Jee et al. (2001) Oncogene 20(2):198-208 “Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency”.
Heinrich et al. (1998) Biochem. J. 334:297-314 “Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway”.
Heinrich et al. (2003) Biochem. J. 374:1-20 “Principles of interleukin (IL)-6-type cytokine signaling and its regulation”.
Klein et al. (1991) Blood 78(5):1198-1204 “Murine Interleukin-6 Monoclonal Antibody Therapy for a Patient with Plasma Cell Leukemia”.
Kurebayashi (2000) Breast Cancer 7(2):124-9 “Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications”.
Liang et al. (2009) J. of Inflammation 6(10):1-12 “Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis”.
Mauray et al. (2000) Eur J Immunol. 30(7):2065-73 “Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6”.
Musselman et al. (2001) Am. J. Psychiatry 158(8):1252-1257 “Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary Findings”.
Okamoto et al. (1997) Cancer Research 57:141-146 “Interleukin-6 as a Paracrine and Autocrine Growth Factor in Human Prostatic Carcinoma Cells in Vitro”.
Sandhu et al. (1999) Bone 24(3):217-27 “Effect of interleukin-6 secreted by engineered human stromal cells on osteo clasts in human bone”.
Schwantner et al. (2004) J. of Biological Chemistry 279(1):571-576 “Direct Determination of the Interleukin-6 Binding Epitope of the Interleukin-6 Receptor by NMR Spectroscopy”.
Smith and Keller (2001) Prostate 48(1):47-53 “Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice”.
Smith et al. (2001) Cytokine and Growth Factor Reviews 12:33-40 “Interleukin-6 and prostate cancer progression”.
Starnes et al. (1990) J. Immunol. 145(12):4185-4191 “Anti-IL-6 Monoclonal Antibodies Protect Against LethalEscherichia coliInfection and Lethal Tumor Necrosis Factor-alpha. Challenge in Mice”.
Strassman et al. (1992) J. Clin. Invest. 89:1681-1684 “Evidence for the Involvement of interleukin 6 in Experimental Cancer Cachexia”.
Van Snick (1990) Ann. Rev. Immunol. 8:253-278 “Interleukin-6. An Overview”.
Weissglas et al. (1997) Endocrinology 138(5):1879-8 “The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice”.
Weissglas et al. (1995) The Journal of Urology 153:554-557 “Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted into Nude Mice”.
International Search Report mailed Jun. 1, 2010 re: PCT/US2009/064321.
Chang Hwai Wen
Akerman & Senterfitt
Femta Pharmaceuticals, Inc.
Shafer Shulamith H
Humanized anti-IL-6 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with Humanized anti-IL-6 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-IL-6 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279657